Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data

被引：0

作者：

Teramoto, Kei ^{[1
]}

Takeda, Toshihiro ^{[2
]}

Matsumura, Yasushi ^{[2
]}

Ohtahara, Akira ^{[3
]}

Hisatome, Ichiro ^{[4
]}

Kondoh, Hiroshi ^{[1
]}

机构：

[1] Tottori Univ Hosp, Div Med Informat, 36-1 Nishi Cho, Tottori 6838504, Japan

[2] Osaka Univ, Med Informat, Grad Sch Med, Osaka, Japan

[3] San In Rosai Hosp, Div Cardiol, Tottori, Japan

[4] Tottori Univ, Inst Regenerat Med & Biofunct, Dept Genet Med & Regenerat Therapeut, Div Regenerat Med & Therapeut,Grad Sch Med Sci, Yonago, Tottori, Japan

来源：

MEDINFO 2019: HEALTH AND WELLBEING E-NETWORKS FOR ALL | 2019年 / 264卷

关键词：

Electronic health records; Pharmacoepidemiology; Antihyperuricemics;

D O I：

10.3233/SHTI190385

中图分类号：

TP39 [计算机的应用];

学科分类号：

081203 ; 0835 ;

摘要：

In this study, treatment and the serum uric acid (UA) level were compared using medication history generated by prescription order records of antihyperuricemic to examine the treatment success rate. We examined the treatment success rate among these patients based on the serum UA level during 120-180 days after the initiation of treatment, which was set as the endpoint. The number of patients whose UA level before the start of treatment was > 8.0 mg/dL but decreased to < 6.0 mg/dL after the treatment, which is the target treatment success, was 92 (success rate of 14.2%), 50 (53.2%), 76 (41.5%), 35 (31.9%), and 45 (37.8%) in the allopurinol 100 mg/day (A1) and 200 mg/day (A2), febuxostat 10 mg/day (F1) and 20 mg/day (F2), and benzbromarone 50 mg/day (B), respectively. Compared with that of the other drugs, the treatment success rate was high with A2 and low with A1. From the generated medication history, the treatment success rate with antihyperuricemic can be extracted mechanically.

引用

页码：1051 / 1055

页数：5

共 50 条

[1] Retention in treatment and therapeutic adherence: How are these associated with therapeutic success? An analysis using real-world data
Dacosta-Sanchez, Daniel
Gonzalez-Ponce, Bella M.
Fernandez-Calderon, Fermin
Sanchez-Garcia, Manuel
Lozano, Oscar M.
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2022, 31 (04)
[2] New Real-World Data on the Treatment using Bempedoic Acid
Schumann, Friederike
Bobbert, Thomas
Steinhagen-Thiessen, Elisabeth
Kassner, Ursula
INTERNIST, 2022, 63 (SUPPL 3): : 351 - 352
[3] Characterizing Treatment Effect Heterogeneity Using Real-World Data
Thelen, Haedi
Hennessy, Sean
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
[4] Real-world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real-world data project
Shimoyama, Rai
Imamura, Yoshinori
Uryu, Kiyoaki
Mase, Takahiro
Fujimura, Yoshiaki
Hayashi, Maki
Ohtaki, Megu
Ohtani, Keiko
Shinozaki, Nobuaki
Minami, Hironobu
MOLECULAR AND CLINICAL ONCOLOGY, 2023, 19 (06)
[5] Real-World Battles with Real-World Data
Brown, Jeffrey
Bate, Andrew
Platt, Robert
Raebel, Marsha
Sauer, Brian
Trifiro, Gianluca
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 254 - 255
[6] Speech translation system applied to a real-world task/domain and its evaluation using real-world speech data
Nakamura, Atsushi, 2001, IEICE of Japan, Tokyo, Japan (E84-D)
[7] A speech translation system applied to a real-world task/domain and its evaluation using real-world speech data
Nakamura, A
Naito, M
Tsukada, H
Gruhn, R
Sumita, E
Kashioka, N
Nakajima, H
Shimizu, T
Sagisaka, Y
IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS, 2001, E84D (01): : 142 - 154
[8] EVALUATION OF 'REAL-WORLD' IPILIMUMAB DATA IN IRELAND
McCullagh, L. M.
Adams, R.
Barry, M.
Schmitz, S.
Walsh, C.
VALUE IN HEALTH, 2015, 18 (07) : A441 - A441
[9] Real-world study: from real-world data to real-world evidence
Wen, Yi
TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
[10] Translating real-world evidence/real-world data
Ravenstijn, Paulien
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (05):

← 1 2 3 4 5 →